mitral heart News
-
Novostia technology for heart valve prosthesis raises CHF 6.5 million to start first clinical trials
Neuchâtel, Switzerland, February 22, 2019 – Novostia announces that it raised CHF 6.5 million from private investors to advance its disruptive aortic and mitral heart valve to clinical trials. Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a heart valve replacement. Available technologies entail serious ...
By Novostia SA
-
New Data Shows The Carillon Mitral Contour System Is Associated With Improvement In Regurgitant Volume In Patients With Increased Mitral Valve Tenting
Cardiac Dimensions, a leader in the development of minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, presented data at the TVT2019 Structural Heart Summit showing increased mitral valve tenting is associated with an improvement in regurgitant volume with the Carillon Mitral Contour System®. The Carillon System is a right-heart ...
-
InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in ...
-
Cardiac Dimensions Announces Australian Therapeutic Goods Administration’s Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System®. The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the ...
-
Cardiac Dimensions Reaches 1,000 Implants of Carillon System, a Minimally Invasive Treatment for Functional Mitral Regurgitation
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Carillon Mitral Contour System® has been implanted in 1,000 patients in the United States, Europe, Australia, Turkey and the Middle East. The Carillon System is a right-heart transcatheter mitral valve ...
-
REDUCE FMR Study Shows Cardiac Dimensions’ Carillon System Significantly Improves Mitral Regurgitation and Slows Worsening of Heart Failure
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the publication of the REDUCE FMR clinical study of its Carillon Mitral Contour System®. The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the primary ...
-
Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. In addition, the Carillon Mitral ...
-
Cardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of the Carillon Mitral Contour System
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the company has closed a $17.5 million Series C financing. All existing shareholders participated in the round including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira ...
-
Cardiac Dimensions Welcomes Robert White to its Board of Directors
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of Directors. Mr. White is a veteran medical technology executive, innovator and strategist with nearly 30 years of experience leading early-stage ...
-
Heat Shuts Down Chicago Marathon
CHICAGO, Illinois, October 8, 2007 (ENS) - One man died and hundreds of other people became ill as temperatures soared into the '80s during the 30th LaSalle Bank Chicago Marathon on Sunday. The race had nearly 36,000 starters from all 50 states and 120 countries. Temperatures were in the low 70s when the race began, but already had climbed into the 80s when the top runners were finishing. It ...
-
New Data Confirms Cardiac Dimensions’ Carillon System Shows Favorable Long-Term Survival Rate in Patients with Functional Mitral Regurgitation
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three studies of the Carillon Mitral Contour System® with a focus on 5-year survival rate and the determinants of long-term ...
-
Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation
Cardiac Dimensions announced a published second individual patient data meta-analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the series of excellent results for this transcatheter-based indirect annuloplasty device. Both of the published ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you